Dietary fatty acids in dementia and predementia syndromes

Epidemiological evidence and possible underlying mechanisms

Vincenzo Solfrizzi, Vincenza Frisardi, Cristiano Capurso, Alessia D'Introno, Anna M. Colacicco, Gianluigi Vendemiale, Antonio Capurso, Francesco Panza

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Drugs currently used in the treatment of cognitive impairment and dementia have a very limited therapeutic value, suggesting the necessity to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. An increasing body of epidemiological evidence suggested that elevated saturated fatty acids (SFA) could have negative effects on age-related cognitive decline (ARCD) and mild cognitive impairment (MCI). Furthermore, a clear reduction of risk for cognitive decline has been found in population samples with elevated fish consumption, high intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), particularly n - 3 PUFA. Epidemiological findings demonstrated that high PUFA intake appeared to have borderline non-significant trend for a protective effect against the development of MCI. Several hypotheses could explain the association between dietary unsaturated fatty acids and cognitive functioning, including mechanisms through the co-presence of antioxidant compounds in food groups rich in fatty acids, via atherosclerosis and thrombosis, inflammation, accumulation of b-amyloid, or via an effect in maintaining the structural integrity of neuronal membranes, determining the fluidity of synaptosomal membranes that thereby regulate neuronal transmission. However, recent findings from clinical trials with n - 3 PUFA supplementation showed efficacy on depressive symptoms only in non-apolipoprotein E (APOE) ε4 carriers, and on cognitive symptoms only in very mild Alzheimer's disease (AD) subgroups, MCI patients, and cognitively unimpaired subjects non-APOE ε4 carriers. These data together with epidemiological evidence support a possible role of fatty acid intake in maintaining adequate cognitive functioning and possibly for the prevention and management of cognitive decline and dementia, but not when the AD process has already taken over.

Original languageEnglish
Pages (from-to)184-199
Number of pages16
JournalAgeing Research Reviews
Volume9
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Dementia
Fatty Acids
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Polyunsaturated fatty acids
Membranes
Monounsaturated Fatty Acids
Fluidity
Structural integrity
Amyloid
Fish
Antioxidants
Association reactions
Alzheimer Disease
Neurobehavioral Manifestations
Membrane Fluidity
Pharmaceutical Preparations
Risk Reduction Behavior
Cognitive Dysfunction
Atherosclerosis

Keywords

  • Age-related cognitive decline
  • Alzheimer's disease
  • Dementia
  • Fatty acids
  • Mild cognitive impairment
  • MUFA
  • Predementia syndromes
  • PUFA
  • Vascular dementia

ASJC Scopus subject areas

  • Ageing
  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Neurology

Cite this

Solfrizzi, V., Frisardi, V., Capurso, C., D'Introno, A., Colacicco, A. M., Vendemiale, G., ... Panza, F. (2010). Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. Ageing Research Reviews, 9(2), 184-199. https://doi.org/10.1016/j.arr.2009.07.005

Dietary fatty acids in dementia and predementia syndromes : Epidemiological evidence and possible underlying mechanisms. / Solfrizzi, Vincenzo; Frisardi, Vincenza; Capurso, Cristiano; D'Introno, Alessia; Colacicco, Anna M.; Vendemiale, Gianluigi; Capurso, Antonio; Panza, Francesco.

In: Ageing Research Reviews, Vol. 9, No. 2, 04.2010, p. 184-199.

Research output: Contribution to journalArticle

Solfrizzi, V, Frisardi, V, Capurso, C, D'Introno, A, Colacicco, AM, Vendemiale, G, Capurso, A & Panza, F 2010, 'Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms', Ageing Research Reviews, vol. 9, no. 2, pp. 184-199. https://doi.org/10.1016/j.arr.2009.07.005
Solfrizzi, Vincenzo ; Frisardi, Vincenza ; Capurso, Cristiano ; D'Introno, Alessia ; Colacicco, Anna M. ; Vendemiale, Gianluigi ; Capurso, Antonio ; Panza, Francesco. / Dietary fatty acids in dementia and predementia syndromes : Epidemiological evidence and possible underlying mechanisms. In: Ageing Research Reviews. 2010 ; Vol. 9, No. 2. pp. 184-199.
@article{926f4466273b48fdb84adb03b4ee4cd5,
title = "Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms",
abstract = "Drugs currently used in the treatment of cognitive impairment and dementia have a very limited therapeutic value, suggesting the necessity to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. An increasing body of epidemiological evidence suggested that elevated saturated fatty acids (SFA) could have negative effects on age-related cognitive decline (ARCD) and mild cognitive impairment (MCI). Furthermore, a clear reduction of risk for cognitive decline has been found in population samples with elevated fish consumption, high intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), particularly n - 3 PUFA. Epidemiological findings demonstrated that high PUFA intake appeared to have borderline non-significant trend for a protective effect against the development of MCI. Several hypotheses could explain the association between dietary unsaturated fatty acids and cognitive functioning, including mechanisms through the co-presence of antioxidant compounds in food groups rich in fatty acids, via atherosclerosis and thrombosis, inflammation, accumulation of b-amyloid, or via an effect in maintaining the structural integrity of neuronal membranes, determining the fluidity of synaptosomal membranes that thereby regulate neuronal transmission. However, recent findings from clinical trials with n - 3 PUFA supplementation showed efficacy on depressive symptoms only in non-apolipoprotein E (APOE) ε4 carriers, and on cognitive symptoms only in very mild Alzheimer's disease (AD) subgroups, MCI patients, and cognitively unimpaired subjects non-APOE ε4 carriers. These data together with epidemiological evidence support a possible role of fatty acid intake in maintaining adequate cognitive functioning and possibly for the prevention and management of cognitive decline and dementia, but not when the AD process has already taken over.",
keywords = "Age-related cognitive decline, Alzheimer's disease, Dementia, Fatty acids, Mild cognitive impairment, MUFA, Predementia syndromes, PUFA, Vascular dementia",
author = "Vincenzo Solfrizzi and Vincenza Frisardi and Cristiano Capurso and Alessia D'Introno and Colacicco, {Anna M.} and Gianluigi Vendemiale and Antonio Capurso and Francesco Panza",
year = "2010",
month = "4",
doi = "10.1016/j.arr.2009.07.005",
language = "English",
volume = "9",
pages = "184--199",
journal = "Ageing Research Reviews",
issn = "1568-1637",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Dietary fatty acids in dementia and predementia syndromes

T2 - Epidemiological evidence and possible underlying mechanisms

AU - Solfrizzi, Vincenzo

AU - Frisardi, Vincenza

AU - Capurso, Cristiano

AU - D'Introno, Alessia

AU - Colacicco, Anna M.

AU - Vendemiale, Gianluigi

AU - Capurso, Antonio

AU - Panza, Francesco

PY - 2010/4

Y1 - 2010/4

N2 - Drugs currently used in the treatment of cognitive impairment and dementia have a very limited therapeutic value, suggesting the necessity to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. An increasing body of epidemiological evidence suggested that elevated saturated fatty acids (SFA) could have negative effects on age-related cognitive decline (ARCD) and mild cognitive impairment (MCI). Furthermore, a clear reduction of risk for cognitive decline has been found in population samples with elevated fish consumption, high intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), particularly n - 3 PUFA. Epidemiological findings demonstrated that high PUFA intake appeared to have borderline non-significant trend for a protective effect against the development of MCI. Several hypotheses could explain the association between dietary unsaturated fatty acids and cognitive functioning, including mechanisms through the co-presence of antioxidant compounds in food groups rich in fatty acids, via atherosclerosis and thrombosis, inflammation, accumulation of b-amyloid, or via an effect in maintaining the structural integrity of neuronal membranes, determining the fluidity of synaptosomal membranes that thereby regulate neuronal transmission. However, recent findings from clinical trials with n - 3 PUFA supplementation showed efficacy on depressive symptoms only in non-apolipoprotein E (APOE) ε4 carriers, and on cognitive symptoms only in very mild Alzheimer's disease (AD) subgroups, MCI patients, and cognitively unimpaired subjects non-APOE ε4 carriers. These data together with epidemiological evidence support a possible role of fatty acid intake in maintaining adequate cognitive functioning and possibly for the prevention and management of cognitive decline and dementia, but not when the AD process has already taken over.

AB - Drugs currently used in the treatment of cognitive impairment and dementia have a very limited therapeutic value, suggesting the necessity to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. An increasing body of epidemiological evidence suggested that elevated saturated fatty acids (SFA) could have negative effects on age-related cognitive decline (ARCD) and mild cognitive impairment (MCI). Furthermore, a clear reduction of risk for cognitive decline has been found in population samples with elevated fish consumption, high intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), particularly n - 3 PUFA. Epidemiological findings demonstrated that high PUFA intake appeared to have borderline non-significant trend for a protective effect against the development of MCI. Several hypotheses could explain the association between dietary unsaturated fatty acids and cognitive functioning, including mechanisms through the co-presence of antioxidant compounds in food groups rich in fatty acids, via atherosclerosis and thrombosis, inflammation, accumulation of b-amyloid, or via an effect in maintaining the structural integrity of neuronal membranes, determining the fluidity of synaptosomal membranes that thereby regulate neuronal transmission. However, recent findings from clinical trials with n - 3 PUFA supplementation showed efficacy on depressive symptoms only in non-apolipoprotein E (APOE) ε4 carriers, and on cognitive symptoms only in very mild Alzheimer's disease (AD) subgroups, MCI patients, and cognitively unimpaired subjects non-APOE ε4 carriers. These data together with epidemiological evidence support a possible role of fatty acid intake in maintaining adequate cognitive functioning and possibly for the prevention and management of cognitive decline and dementia, but not when the AD process has already taken over.

KW - Age-related cognitive decline

KW - Alzheimer's disease

KW - Dementia

KW - Fatty acids

KW - Mild cognitive impairment

KW - MUFA

KW - Predementia syndromes

KW - PUFA

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=77949322655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949322655&partnerID=8YFLogxK

U2 - 10.1016/j.arr.2009.07.005

DO - 10.1016/j.arr.2009.07.005

M3 - Article

VL - 9

SP - 184

EP - 199

JO - Ageing Research Reviews

JF - Ageing Research Reviews

SN - 1568-1637

IS - 2

ER -